Microbot Medical (NASDAQ:MBOT – Get Free Report) and IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.
Analyst Recommendations
This is a breakdown of current ratings and target prices for Microbot Medical and IDEXX Laboratories, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 1 | 1 | 1 | 0 | 2.00 |
| IDEXX Laboratories | 0 | 4 | 7 | 0 | 2.64 |
Microbot Medical currently has a consensus target price of $12.00, indicating a potential upside of 435.71%. IDEXX Laboratories has a consensus target price of $730.50, indicating a potential upside of 0.21%. Given Microbot Medical’s higher possible upside, equities analysts plainly believe Microbot Medical is more favorable than IDEXX Laboratories.
Risk and Volatility
Profitability
This table compares Microbot Medical and IDEXX Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -76.27% | -67.54% |
| IDEXX Laboratories | 24.41% | 64.42% | 29.89% |
Insider and Institutional Ownership
16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 87.8% of IDEXX Laboratories shares are held by institutional investors. 4.7% of Microbot Medical shares are held by insiders. Comparatively, 1.0% of IDEXX Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation & Earnings
This table compares Microbot Medical and IDEXX Laboratories”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$11.44 million | ($0.45) | -4.98 |
| IDEXX Laboratories | $4.17 billion | 13.97 | $887.87 million | $12.61 | 57.81 |
IDEXX Laboratories has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.
Summary
IDEXX Laboratories beats Microbot Medical on 11 of the 13 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
